open access
The predictive value of the first trimester combined test for gestational diabetes mellitus
, 1, 1, 2
Affiliations- Department of Obstetrics and Gynecology, Atatürk Training and Research Hospital, Izmir Kâtip Çelebi University, Karabağlar, Izimir, Turkey
- Health Sciences University, Dr Suat Seren Chest Diseases and Chest Surgery Training and Research Hospital, Yenişehir, Izmir, Turkey
open access
Abstract
Objectives: To investigate the predictive importance of first trimester combined test markers pregnancy-associated plasma protein-A (PAPP-A), human chorionic gonadotropin β (β-hCG) and nuchal translucency (NT) for gestational diabetes mellitus (GDM).
Material and methods: Pregnant women which both first trimester combined test and GDM screening were performed during antenatal follow-up were included in this retrospective case-control study. The cases were divided into two groups as GDM screening positive and negative. Demographic, clinical and laboratory data of both groups were compared. Predictive tests were applied to the first trimester combined test data for the detection of GDM.
Results: A total of 378 patients, 171 (45.2%) in the control group and 207 (54.8%) in the GDM group. The age (control: 30.9 ± 5.2; GDM: 30.5 ± 5.1; p = 0.844) and NT (control: 1.254 ± 0.289; GDM: 1.319 ± 0.299; p = 0.074) data of the groups were statistically similar.
MoM PAPP-A (GDM:0.967 ± 0.685; ontrol:1.191 ± 0.624; p < 0.001) and MoM f-βhCG (GDM: 0.9 ± 0.602; control: 1.103 ± 0.746; p = 0.001) levels of the GDM group were lower than the control group.
In the binary logistic regression model, MoM PAPP-A and MoM f-βhCG variables were found to be effective on GDM. In the ROC analysis of these variables, the MoM PAPP-A (0.654) had the highest area under the curve. According to the optimum cut-off point (≤ 0.885) of the MoM PAPP-A, we found a sensitivity of 66.7% and a specificity of 65.50% for predicting GDM.
Conclusions: Our study showed that serum PAPP-A and f-βhCG MoM values, which are among the first trimester combined test parameters, can be used in the early pregnancy period for the prediction of GDM.
Abstract
Objectives: To investigate the predictive importance of first trimester combined test markers pregnancy-associated plasma protein-A (PAPP-A), human chorionic gonadotropin β (β-hCG) and nuchal translucency (NT) for gestational diabetes mellitus (GDM).
Material and methods: Pregnant women which both first trimester combined test and GDM screening were performed during antenatal follow-up were included in this retrospective case-control study. The cases were divided into two groups as GDM screening positive and negative. Demographic, clinical and laboratory data of both groups were compared. Predictive tests were applied to the first trimester combined test data for the detection of GDM.
Results: A total of 378 patients, 171 (45.2%) in the control group and 207 (54.8%) in the GDM group. The age (control: 30.9 ± 5.2; GDM: 30.5 ± 5.1; p = 0.844) and NT (control: 1.254 ± 0.289; GDM: 1.319 ± 0.299; p = 0.074) data of the groups were statistically similar.
MoM PAPP-A (GDM:0.967 ± 0.685; ontrol:1.191 ± 0.624; p < 0.001) and MoM f-βhCG (GDM: 0.9 ± 0.602; control: 1.103 ± 0.746; p = 0.001) levels of the GDM group were lower than the control group.
In the binary logistic regression model, MoM PAPP-A and MoM f-βhCG variables were found to be effective on GDM. In the ROC analysis of these variables, the MoM PAPP-A (0.654) had the highest area under the curve. According to the optimum cut-off point (≤ 0.885) of the MoM PAPP-A, we found a sensitivity of 66.7% and a specificity of 65.50% for predicting GDM.
Conclusions: Our study showed that serum PAPP-A and f-βhCG MoM values, which are among the first trimester combined test parameters, can be used in the early pregnancy period for the prediction of GDM.
Keywords
gestational diabetes; pregnancy-associated plasma protein-A; chorionic gonadotropin; nuchal translucency
About this articleTitle
The predictive value of the first trimester combined test for gestational diabetes mellitus
Journal
Issue
Article type
Research paper
Pages
395-399
Published online
2022-05-06
Page views
1913
Article views/downloads
505
DOI
Pubmed
Bibliographic record
Ginekol Pol 2023;94(5):395-399.
Keywords
gestational diabetes
pregnancy-associated plasma protein-A
chorionic gonadotropin
nuchal translucency
Authors
Aşkin Yildiz
Simge Tezel Yozgat
Hakan Cokmez
Fatma Şebnem Yildiz
References (26)- Plows JF, Stanley JL, Baker PN, et al. The Pathophysiology of Gestational Diabetes Mellitus. Int J Mol Sci. 2018; 19(11).
- Hod M, Kapur A, Sacks D, et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care#. International Journal of Gynecology & Obstetrics. 2015; 131: S173.
- Morris RK, Bilagi A, Devani P, et al. Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta-analysis. Prenat Diagn. 2017; 37(3): 253–265.
- Visconti F, Quaresima P, Chiefari E, et al. First Trimester Combined Test (FTCT) as a Predictor of Gestational Diabetes Mellitus. Int J Environ Res Public Health. 2019; 16(19).
- Savvidou M, Nelson SM, Makgoba M, et al. First-trimester prediction of gestational diabetes mellitus: examining the potential of combining maternal characteristics and laboratory measures. Diabetes. 2010; 59(12): 3017–3022.
- Kulaksizoglu S, Kulaksizoglu M, Kebapcilar AG, et al. Can first-trimester screening program detect women at high risk for gestational diabetes mellitus? Gynecol Endocrinol. 2013; 29(2): 137–140.
- Chiefari E, Arcidiacono B, Foti D, et al. Gestational diabetes mellitus: an updated overview. J Endocrinol Invest. 2017; 40(9): 899–909.
- Talasaz ZH, Sadeghi R, Askari F, et al. First trimesters Pregnancy-Associated Plasma Protein-A levels value to Predict Gestational diabetes Mellitus: A systematic review and meta-analysis of the literature. Taiwan J Obstet Gynecol. 2018; 57(2): 181–189.
- Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2011; 34(Supplement_1): S62–S69.
- Beneventi F, Simonetta M, Lovati E, et al. First trimester pregnancy-associated plasma protein-A in pregnancies complicated by subsequent gestational diabetes. Prenat Diagn. 2011; 31(6): 523–528.
- Beneventi F, Simonetta M, Locatelli E, et al. Temporal variation in soluble human leukocyte antigen-G (sHLA-G) and pregnancy-associated plasma protein A (PAPP-A) in pregnancies complicated by gestational diabetes mellitus and in controls. Am J Reprod Immunol. 2014; 72(4): 413–421.
- Sweeting AN, Wong J, Appelblom H, et al. A first trimester prediction model for gestational diabetes utilizing aneuploidy and pre-eclampsia screening markers. J Matern Fetal Neonatal Med. 2018; 31(16): 2122–2130.
- Xiao Di, Chenhong W, Yanbin Xu, et al. Gestational diabetes mellitus and first trimester pregnancy-associated plasma protein A: A case-control study in a Chinese population. J Diabetes Investig. 2018; 9(1): 204–210.
- Ong CY, Liao AW, Spencer K, et al. First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG. 2000; 107(10): 1265–1270.
- Spencer K, Cowans NJ. The association between gestational diabetes mellitus and first trimester aneuploidy screening markers. Ann Clin Biochem. 2013; 50(Pt 6): 603–610.
- Morris RK, Bilagi A, Devani P, et al. Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta-analysis. Prenat Diagn. 2017; 37(3): 253–265.
- Farina A, Eklund E, Bernabini D, et al. A First-Trimester Biomarker Panel for Predicting the Development of Gestational Diabetes. Reprod Sci. 2017; 24(6): 954–959.
- Wells G, Bleicher K, Han X, et al. Maternal Diabetes, Large-for-Gestational-Age Births, and First Trimester Pregnancy-Associated Plasma Protein-A. J Clin Endocrinol Metab. 2015; 100(6): 2372–2379.
- Lovati E, Beneventi F, Simonetta M, et al. Gestational diabetes mellitus: including serum pregnancy-associated plasma protein-A testing in the clinical management of primiparous women? A case-control study. Diabetes Res Clin Pract. 2013; 100(3): 340–347.
- Syngelaki A, Kotecha R, Pastides A, et al. First-trimester biochemical markers of placentation in screening for gestational diabetes mellitus. Metabolism. 2015; 64(11): 1485–1489.
- Tul N, Pusenjak S, Osredkar J, et al. Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A. Prenat Diagn. 2003; 23(12): 990–996.
- Savvidou MD, Syngelaki A, Muhaisen M, et al. First trimester maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein A in pregnancies complicated by diabetes mellitus. BJOG. 2012; 119(4): 410–416.
- Cheuk QKy, Lo TK, Wong SF, et al. Association between pregnancy-associated plasma protein-A levels in the first trimester and gestational diabetes mellitus in Chinese women. Hong Kong Med J. 2016; 22(1): 30–38.
- Husslein H, Lausegger F, Leipold H, et al. Association between pregnancy-associated plasma protein-A and gestational diabetes requiring insulin treatment at 11-14 weeks of gestation. J Matern Fetal Neonatal Med. 2012; 25(11): 2230–2233.
- Lovati E, Beneventi F, Simonetta M, et al. Gestational diabetes mellitus: including serum pregnancy-associated plasma protein-A testing in the clinical management of primiparous women? A case-control study. Diabetes Res Clin Pract. 2013; 100(3): 340–347.
- Leipold H, Worda C, Ozbal A, et al. First-trimester nuchal translucency screening in pregnant women who subsequently developed gestational diabetes. J Soc Gynecol Investig. 2005; 12(7): 529–532.
